Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression

Inclusion Criteria: The patients must fulfill all of the following criteria: The patient has confirmed his/her willingness to participate in the study, after being informed about all the aspects of the study that might be relevant for his/her decision to participate, and has signed and dated the informed consent form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC). And he/she can withdraw the study participation at any moment, if he/she wants to do so. The patient has laboratorial confirmation of an HIV infection through a positive ELISA test for anti-HIV antibodies and an additional test (Western-blot, indirect immunofluorescence or PCR). The patient must be in treatment with at least three antiretroviral drugs, for at least 6 months without changes. The patient should have no history of documented virological failure to previously used antiretroviral therapies. Undetectable viral load (test result < 400 copies/ml) for more than 6 months measured on a sample collected during treatment with the current regimen and at screening (test result < 80 copies). CD4 count > 200 cels/ml at screening Patient agrees not to use concomitant medication that might have unacceptable drug interactions with the study drug. If the patient is a female, she must have a negative pregnancy test and must agree to use at least 14 days before the study drug administration and for the whole study duration and up to 6 months after, a barrier contraceptive method with a proven reliability track record, as judged by the investigator Exclusion Criteria: Pregnant or lactating female patient. If the patient becomes pregnant during the study, she will be discontinued from the study. Patients with allergic reaction or hypersensitivity to Lopinavir or Ritonavir . A patient with previous history of opportunistic disease ( appendix 1) or CD4 count below 100 cels/mm3. A patient who presents any HIV viral load test result above 400 copies/mL over the past 6 months. Patient who is receiving or has received systemic chemotherapy during the past 6 months. Laboratory test results Hemoglobin < 8 g/dl Absolute neutrophil count < 750 cels/mL Platelet count < 20,000/mL Bilirubin > 1.5 x UNL or > 6 x UNL if patient is using Indinavir or Atazanavir ALT and AST > 2 x UNL Creatinine > 2 x UNL Patient is taking any drug known to be contraindicated concomitantly with lopinavir/r. Please refer to the product's package insert. According to the investigator's opinion, the patient has little probability of complying with the study protocol or is unsuitable for any other reason.